Strategy ( (MSTR)) just unveiled an update. On March 23, 2026, Strategy Inc. expanded its Omnibus Sales Agreement by adding Moelis & Company, A.G.P./Alliance Global Partners and StoneX Financial as ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

President Donald Trump speaks before signing an executive order on fraud in the Oval Office at the White House in Washington, D.C., on March 16, 2026, as Vice President JD Vance looks on. (Photo by ...

Ingo Swann participated in classified experiments involving remote viewing. According to his account, he observed structures on the Moon. Dietitians say you shouldn't take these vitamins in the ...

Abstract: As an ordered extension of evidence theory, Random permutation set (RPS) theory has received increasing attention due to its advantage in dealing with order-structured uncertain information.

Integrating artificial intelligence into business areas, adopting global AI-based platforms, and building a robust ecosystem with technological partnerships—these were the three pillars on which ...

Loyalty programs were once designed to thank customers for sticking around. This could include perks like free coffee, airline miles, or grocery discounts in exchange for repeat business. But that ...

FSU athletics director Michael Alford was flanked by newly appointed general manager of player personnel John Garrett and head coach Mike Norvell on Wednesday as the trio tasked with repairing the ...

CNBC ranks the 75 most valuable college athletic programs. The programs are worth a combined $51.22 billion, 13% more than the top 75 in last year's rankings. Earlier this month the University of Utah ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...